Comparative in vitro enzyme activities of five commercially available pancreatic supplements.
A comparative in vitro analysis was performed of the enzyme activities contained in five commercial pancreatic supplements available in New Zealand. there was considerable individual variation between each product. Lipase was regarded as the most important enzyme, as lipase deficiency is the most significant clinical factor in patients with exocrine pancreatic insufficiency. Viokase not only contained the most lipase per tablet, but was also the cheapest product.
D000681:Amylases / Q000032:analysis*; D002214:Capsules; D002918:Chymotrypsin / Q000032:analysis*; D004338:Drug Combinations / Q000032:analysis; D006026:Glycoside Hydrolases / Q000032:analysis*; D006801:Humans; D008049:Lipase / Q000032:analysis*; D010184:Pancreatic Extracts / Q000032:analysis*; D020799:Pancrelipase; D010447:Peptide Hydrolases / Q000032:analysis*; D013608:Tablets, Enteric-Coated; D014357:Trypsin / Q000032:analysis*
D002214:Capsules; D004338:Drug Combinations; D010184:Pancreatic Extracts; D013608:Tablets, Enteric-Coated; D020799:Pancrelipase; C005335:Combizym; D008049:Lipase; D000681:Amylases; D006026:Glycoside Hydrolases; D010447:Peptide Hydrolases; D002918:Chymotrypsin; D014357:Trypsin